If amyloid deposition is found to be higher in people who have Down syndrome, understanding which gene on chromosome 21 other than APP contributes to this will provide novel insights into disease development and may provide a new target for drug therapy for individuals who have Down syndrome, who are at extraordinarily high risk of developing dementia. The gene discussed is APP; the disease is dementia.